Market Snapshot

S&P Futures
4,197.75
Dow Futures
34,466.00
NASDAQ Futures
13,617.50

9.43$-0.60 -5.98%
At close    04:00 PM   
From: To:

Stock Snapshot

10.03
Prev. Close
9.96
Open
468.67M
Market Cap
2.94M
Number of Shares
9.23
Day Low
10.04
Day High
9.43
-
P/E Ratio
27.05M
Free Float in %
-2.42
EPS 2021
1.71
Book Value per Share
-
Cash Flow per Share
Evelo Biosciences, Inc. (EVLO)
Evelo Biosciences, Inc. (EVLO) stock rallied over -5.98% intraday to trade at $9.43 per share on NASDAQ. The stock opened with a fall of -0.70% at $9.96 and touched an intraday high of $10.04, rising 0.10% against the last close of $10.03. The stock went to a low of $9.23 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-05-06$9.96$9.43$9.43$10.04$9.23103,482
2021-05-05$10.57$10.03$10.03$10.57$9.86214,900
2021-05-04$10.61$10.35$10.35$10.76$10.01271,100
2021-05-03$12.87$10.57$10.57$12.96$10.50441,500
2021-04-30$12.13$13.15$13.15$13.17$12.10160,100
2021-04-29$12.40$12.24$12.24$12.50$11.83192,800
2021-04-28$12.32$12.09$12.09$12.42$11.66105,000
2021-04-27$12.30$12.42$12.42$12.65$12.1176,000
2021-04-26$11.66$12.24$12.24$12.50$11.60124,800
2021-04-23$11.23$11.54$11.54$11.68$11.0160,600
2021-04-22$11.88$11.16$11.16$12.21$11.00198,900
Evelo Biosciences, Inc.
620 Memorial Drive
5th Floor
Cambridge, MA 02139
United States

http://www.evelobio.com
617 577 0300
Employees
90
Sector
Healthcare
Sales or Revenue
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
2020-12-30
Dr. Balkrishan Gill
Pres, CEO, Treasurer, Principal Financial Officer & Director
Dr. Mark Bodmer
Chief Scientific Officer and Pres of R&D
Ms. Xiaoli Liu
Controller & Principal Accounting Officer
Evelo Biosciences, Inc.
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a monoclonal microbial candidate, which is in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of psoriasis or atopic dermatitis. The company is also developing monoclonal microbial candidates, which are in pre-clinical development stage include EDP1815 for treating psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthritis; EDP1867 for asthma; EDP2939 for inflammatory disease; and EDP1632 for neuro-inflammatory diseases. In addition, it is developing EDP1503, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.